UniQure’s Huntington’s Disease Therapy Approval Blocked by FDA Amid Regulatory Concerns
UniQure announced on Monday that its efforts to secure approval for a Huntington’s disease treatment from the Food and Drug Administration (FDA) remain obstructed, marking another hurdle for a therapy that previously seemed poised for approval. In a recent meeting with the FDA, UniQure learned that regulators remain unconvinced that the data from its completed…









